Synthesis, characterisation and biological evaluation of copper and silver complexes based on acetylsalicylic acid

Archiv der Pharmazie

Volumn 344, Issue 10, 2011, Pages 684-688

  Rubner, Gerhard ^a   Bensdorf, Kerstin ^a   Wellner, Anja ^a   Bergemann, Silke ^a   Gust, Ronald ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Acetylsalicylic acid; Copper; Cyclooxygenase; Cytotoxicity; Silver; Transition metal complexes

Indexed keywords

[(BUT 2 YNE 1,4 DIYL)BIS(2 ACETOXYBENZOATE)]COPPERTRIFLUOROMETHANESULFONATE; [(BUT 2 YNE 1,4 DIYL)BIS(2 ACETOXYBENZOATE)]SILVERTRIFLUOROMETHANESULFONATE; [(BUT 3 YNYL 2) 2 ACETOXYBENZOATE]COPPERTRIFLUOROMETHANESULFONATE; [(BUT 3 YNYL 2) 2 ACETOXYBENZOATE]SILVERTRIFLUOROMETHANESULFONATE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; COPPER; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; SILVER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; COLON CANCER; COMPLEX FORMATION; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENZYME INHIBITION; EVALUATION; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ASPIRIN; CELL LINE, TUMOR; CELL SURVIVAL; COPPER; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; SILVER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053933130     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201000382     Document Type: Article

References (15)

1. A. Gelasco, S. Lippard, J. Topics Bioinorg. Chem. 1999, 1, 1-43.
2. E. R. Jamieson, S. J. Lippard, Chem. Rev. 1999, 99, 2467-2498.
3. L. C. Hsi, S. Joon Baek, T. E. Eling, Exp. Cell Res. 2000, 256, 563-570.
4. J. Karl, R. Gust, T. Spruss, M. R. Schneider, H. Schoenenberger, J. Engel, K. H. Wrobel, F. Lux, S. T. Haeberlin, J. Med. Chem. 1988, 31, 72-83.
5. R. Gust, T. Burgemeister, A. Mannschreck, H. Schoenenberger, J. Med. Chem. 1990, 33, 2535-2544.
6. R. Gust, H. Schoenenberger, Eur. J. Med. Chem. 1993, 28, 103-115.
7. R. Gust, Arch. Pharm. 1994, 327, 49-54.
8. R. Gust, K. Niebler, H. Schoenenberger, J. Med. Chem. 1995, 38, 2070-2079.
9. I. Ott, B. Kircher, C. P. Bagowski, D. H. W. Vlecken, E. B. Ott, J. Will, K. Bensdorf, W. S. Sheldrick, R. Gust, Angew. Chem. Int. Ed. 2009, 48, 1160-1163.
10. I. Ott, K. Schmidt, B. Kircher, P. Schumacher, T. Wiglenda, R. Gust, J. Med. Chem. 2005, 48, 622-629.
11. G. Rubner, K. Bensdorf, A. Wellner, B. Kircher, S. Bergemann, I. Ott, R. Gust, J. Med. Chem. 2010, 53, 6889-6898.
12. G. Rubner, K. Bensdorf, A. Wellner, S. Bergemann, I. Ott, R. Gust, Eur. J. Med. Chem. 2010, 45, 5157-5163.
13. G. S. Lewandos, D. K. Gregston, F. R. Nelson, J. Organomet. Chem. 1976, 118, 363-374.
14. X.-H. Liu, D. P. Rose, Cancer Res. 1996, 56, 5125-5127.
15. R. J. Hay, Anal. Biochem. 1988, 171, 225-237.